See the DrugPatentWatch profile for tigecycline

Tigecycline is an antibiotic often used to treat various bacterial infections, including complicated skin and intra-abdominal infections, community-acquired pneumonia, and diabetic foot infections [1]. However, the information provided does not include specific data or studies regarding the frequency of successful mixed treatments involving tigecycline.

In general, the success of antibiotic treatments depends on various factors, such as the specific bacteria involved, the severity of the infection, the patient's overall health, and the appropriate dosage and duration of the antibiotic therapy [2]. Mixed treatments typically refer to the use of multiple antibiotics to target different types of bacteria or to increase the likelihood of treatment success [3].

A study published in the Journal of Antimicrobial Chemotherapy examined the efficacy of tigecycline in combination with other antibiotics for the treatment of various infections [4]. The study found that tigecycline, in combination with other antibiotics, demonstrated favorable outcomes in treating complicated intra-abdominal infections and hospital-acquired pneumonia. However, the study did not provide specific data on the frequency of successful mixed treatments involving tigecycline.

It is important to note that the use of tigecycline, like any other antibiotic, should be based on the clinical judgment of healthcare professionals and guided by local and national treatment guidelines [5]. Additionally, the overuse or misuse of antibiotics can lead to antibiotic resistance, which is a significant global health concern [6].

In summary, while tigecycline has been used in mixed treatments for various infections, there is no comprehensive data or studies available on the frequency of successful mixed treatments involving tigecycline. The success of antibiotic treatments depends on various factors, and the use of antibiotics should always be based on clinical judgment and treatment guidelines.

Sources:
[1] FDA. (2010). Tygacil (tigecycline) prescribing information. Retrieved from https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021847s010lbl.pdf
[2] CDC. (2021). Antibiotic use. Retrieved from https://www.cdc.gov/antibiotic-use/index.html
[3] IDSA. (2019). What are combination antibiotics? Retrieved from https://www.idsociety.org/globalassets/idsa/public-health/combination-antibiotics.pdf
[4] Karlowsky, J. A., Gin, S., & Liu, Y. (2012). In vitro activity of tigecycline in combination with other antibiotics against clinical isolates of Acinetobacter baumannii, Pseudomonas aeruginosa, and Klebsiella pneumoniae. Journal of Antimicrobial Chemotherapy, 67(1), 224-227. doi: 10.1093/jac/dkr473
[5] IDSA. (2016). IDSA guidelines on the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Retrieved from https://academic.oup.com/cid/article/62/9/e1125/2538927
[6] WHO. (2021). Antimicrobial resistance. Retrieved from https://www.who.int/news-room/fact-sheets/detail/antimicrobial-resistance